Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice

Receptor activator of NF‐κB ligand (RANKL) plays a key role in osteoclast‐induced bone resorption across a range of degenerative bone diseases, and its specific inhibition has been recently approved as a treatment for women with postmenopausal osteoporosis at high or increased risk of fracture in the United States and globally. In the present study, we generated transgenic mice (TghuRANKL) carrying the human RANKL (huRANKL) genomic region and achieved a physiologically relevant pattern of RANKL overexpression in order to establish novel genetic models for assessing skeletal and extraskeletal pathologies associated with excessive RANKL and for testing clinical therapeutic candidates that inhibit human RANKL. TghuRANKL mice of both sexes developed early‐onset bone loss, and the levels of huRANKL expression were correlated with bone resorption and disease severity. Low copy Tg5516 mice expressing huRANKL at low levels displayed a mild osteoporotic phenotype as shown by trabecular bone loss and reduced biomechanical properties. Notably, overexpression of huRANKL, in the medium copy Tg5519 line, resulted in severe early‐onset osteoporosis characterized by lack of trabecular bone, destruction of the growth plate, increased osteoclastogenesis, bone marrow adiposity, increased bone remodeling, and severe cortical bone porosity accompanied by decreased bone strength. An even more severe skeletal phenotype developed in the high copy Tg5520 founder with extensive soft tissue calcification. Model validation was further established by evidence that denosumab, an antibody that inhibits human but not murine RANKL, fully corrected the hyper‐resorptive and osteoporotic phenotypes of Tg5519 mice. Furthermore, overexpression of huRANKL rescued osteopetrotic phenotypes of RANKL‐defective mice. These novel huRANKL transgenic models of osteoporosis represent an important advance for understanding the pathogenesis and treatment of high‐turnover bone diseases and other disease states caused by excessive RANKL. © 2014 American Society for Bone and Mineral Research.

[1]  H. Takayanagi,et al.  Osteocyte control of osteoclastogenesis. , 2013, Bone.

[2]  A. Villa,et al.  RANKL Cytokine: From Pioneer of the Osteoimmunology Era to Cure for a Rare Disease , 2013, Clinical & developmental immunology.

[3]  P. Kostenuik,et al.  Osteopetrosis rescue upon RANKL administration to Rankl−/− mice: A new therapy for human RANKL‐dependent ARO , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  Xinquan Wang,et al.  Crystal Structure of Human RANKL Complexed with Its Decoy Receptor Osteoprotegerin , 2012, The Journal of Immunology.

[5]  A. Munnich,et al.  An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth. , 2012, Human molecular genetics.

[6]  George Kollias,et al.  A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. , 2012, Human molecular genetics.

[7]  Ian Pyrah,et al.  Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. , 2011, Bone.

[8]  P. Kostenuik,et al.  Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. , 2011, Bone.

[9]  Xiaojuan Li,et al.  Quantification of vertebral bone marrow fat content using 3 tesla MR spectroscopy: Reproducibility, vertebral variation, and applications in osteoporosis , 2011, Journal of magnetic resonance imaging : JMRI.

[10]  J. Penninger,et al.  RANKL/RANK—beyond bones , 2011, Journal of Molecular Medicine.

[11]  R. Effros,et al.  PKA-induced Receptor Activator of NF-κB Ligand (RANKL) Expression in Vascular Cells Mediates Osteoclastogenesis but Not Matrix Calcification* , 2010, The Journal of Biological Chemistry.

[12]  C. O’Brien Control of RANKL gene expression. , 2010, Bone.

[13]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[14]  P. Kostenuik,et al.  Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. , 2009, Bone.

[15]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[16]  P. Kostenuik,et al.  Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. , 2009, The American journal of pathology.

[17]  A. Klibanski,et al.  Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. , 2009, The American journal of medicine.

[18]  T. Saunders,et al.  Generating transgenic mice from bacterial artificial chromosomes: transgenesis efficiency, integration and expression outcomes , 2009, Transgenic Research.

[19]  P. Kostenuik,et al.  Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock‐In Mice That Express Chimeric (Murine/Human) RANKL , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Penninger,et al.  RANK/RANKL: Regulators of Immune Responses and Bone Physiology , 2008, Annals of the New York Academy of Sciences.

[21]  Andrei L. Turinsky,et al.  Age-dependent change in the 3D structure of cortical porosity at the human femoral midshaft. , 2007, Bone.

[22]  Hong Yang,et al.  Downregulation of beta-catenin and transdifferentiation of human osteoblasts to adipocytes under estrogen deficiency , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[23]  M. Bouxsein,et al.  Ovariectomy‐Induced Bone Loss Varies Among Inbred Strains of Mice , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  C. Laplace,et al.  Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo , 2004, The Journal of cell biology.

[25]  D. Lacey,et al.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. , 2003, The Journal of clinical investigation.

[26]  H. Yasuda,et al.  Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis , 2002, Journal of Bone and Mineral Metabolism.

[27]  E. Wagner,et al.  Reaching a genetic and molecular understanding of skeletal development. , 2002, Developmental cell.

[28]  Yongwon Choi,et al.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D L Lacey,et al.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.

[30]  T. Martin,et al.  Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.

[31]  Yongwon Choi,et al.  TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts , 1998, The Journal of experimental medicine.

[32]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[33]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[34]  A. Darby BONE FORMATION AND RESORPTION IN POSTMENOPAUSAL OSTEOPOROSIS , 1981, The Lancet.

[35]  Mary L Bouxsein,et al.  Mechanisms of Disease: is osteoporosis the obesity of bone? , 2006, Nature Clinical Practice Rheumatology.

[36]  S. Hagl,et al.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. , 2004, Journal of molecular and cellular cardiology.

[37]  G. Kollias,et al.  Genetic engineering in the mouse: tuning TNF/TNFR expression. , 2004, Methods in molecular medicine.

[38]  G. Kollias,et al.  Genetic Engineering in the Mouse , 2004 .